Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of over $270 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates.

We also have number of additional partnerships under negotiation. These partnership agreements represent the start of CEPI’s product development portfolio. See below current details of our vaccine portfolio.

PRODUCT DEVELOPERS
  • All
  • CureVac
  • IDT Biologika
  • Imperial College London
  • Inovio Pharmaceuticals
  • International AIDS Vaccine Initiative
  • Janssen Vaccines & University of Oxford
  • Profectus Biosciences, Emergent Biosolutions & PATH
  • Themis Bioscience
  • University of Queensland
DISEASE
  • All
  • Chikungunya
  • Lassa virus
  • Marburg virus
  • MERS coronavirus
  • Nipah virus
VACCINE TYPE
  • All
  • Nucleic acid
  • Recombinant protein
  • Recombinant virus
PHASE
  • All
  • Phase 1
  • Phase 2
  • Phase 3
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:

{{ dev['funding_title'] }}

{{ dev['funding'] }}

{{ d['disease'] }}
{{ d['vaccine_type'] }}
{{ d['trial_title'] }}
{{ d['trial'] }}
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result